ACADIA Pharmaceuticals Inc. ((ACAD)) has held its Q2 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ACADIA Pharmaceuticals Inc. recently held its earnings call, revealing a positive sentiment driven by strong revenue growth and strategic initiatives. The company showcased impressive sales figures for its key products, DAYBUE and NUPLAZID, and highlighted successful direct-to-consumer campaigns. Despite concerns regarding increased SG&A expenses and risks associated with pipeline development, the overall outlook remains optimistic.
Strong Revenue Growth
ACADIA Pharmaceuticals reported a total revenue of $264.6 million for Q2 2025, marking a 9% increase compared to the previous year. This growth was primarily fueled by the sales of DAYBUE and NUPLAZID, underscoring the company’s robust commercial performance.
DAYBUE Sales Increase
The sales of DAYBUE reached $96.1 million in Q2 2025, reflecting a 14% year-over-year increase. This growth was supported by a rise in unique patient shipments, demonstrating the product’s expanding market presence.
NUPLAZID Revenue Growth
NUPLAZID generated $168.5 million in revenue for Q2 2025, a 7% increase from the previous year. The growth was attributed to improved prescription volumes, highlighting the product’s strong demand in the market.
Pipeline Expansion
ACADIA is actively advancing its pipeline with nine disclosed programs, including anticipated Phase II and III studies. The company expects significant readouts from 2025 to 2027, indicating a promising future for its research and development efforts.
Successful Direct-to-Consumer Campaigns
The direct-to-consumer campaigns for DAYBUE and NUPLAZID have been successful in driving consumer engagement and increasing new prescriptions. This strategic approach has contributed to the company’s revenue growth and market penetration.
Increased SG&A Expenses
SG&A expenses rose to $133.5 million in Q2 2025, up from $117.1 million the previous year. The increase was primarily due to higher expenditures related to DAYBUE and NUPLAZID, reflecting the company’s investment in its growth initiatives.
Pipeline Development Risks
ACADIA acknowledged the ongoing risks and uncertainties associated with pipeline development, including clinical trial outcomes and regulatory approvals. These factors remain critical considerations for the company’s future growth.
Forward-Looking Guidance
During the earnings call, ACADIA provided financial guidance for 2025, raising the lower end of its full-year NUPLAZID revenue guidance to $665-$690 million. The company emphasized strong commercial execution and positive momentum from its direct-to-consumer campaign. Additionally, ACADIA plans to initiate seven Phase II or III studies and anticipates five data readouts between 2025 and 2027, reinforcing its commitment to pipeline advancement.
In summary, ACADIA Pharmaceuticals Inc.’s earnings call reflected a positive sentiment, driven by strong revenue growth and strategic initiatives. The company’s focus on expanding its pipeline and successful direct-to-consumer campaigns are key highlights. Despite challenges related to increased SG&A expenses and pipeline development risks, ACADIA remains confident in achieving its financial targets and sustaining its growth trajectory.